CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. (CALC) reported that Stephen Bardin, its Chief Financial Officer, principal accounting officer and principal financial officer, gave notice of resignation on October 15, 2026. His resignation is to take effect immediately following the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The stated reason is to pursue another professional opportunity, and the resignation was not due to any disagreement with the company.
CalciMedica, Inc. director Alan Glicklich acquired a director stock option on October 1, 2026, covering the right to buy 20,000 common shares. The option has a $1.64 exercise price and expires September 30, 2036. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over one year; the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders.
CalciMedica, Inc. reported director Evgeny Zaytsev's grant of 20,000 director stock options on October 1, 2026. The options cover 20,000 shares of common stock, carry a $1.64 exercise price, and expire September 30, 2036; after the grant, Zaytsev reported holding 20,000 options directly.
CalciMedica, Inc. director Frederic Guerard acquired a director stock option on October 1, 2026, covering 20,000 shares of common stock. The option has an exercise price of $1.64 per share and expires September 30, 2036. After the award, his reported direct option position covered 20,000 shares.
Beginning August 19, 2026, one-twelfth of the shares subject to the option vest in equal monthly installments over one year. The option will be fully vested on the date of CalciMedica's 2027 annual meeting.
CalciMedica, Inc. director Allan Shaw acquired a grant of 20,000 director stock options on October 1, 2026, covering 20,000 shares of Common Stock. The options have an exercise price of $1.64 per share and expire September 30, 2036. Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over one year; the option will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders.
CalciMedica, Inc. director Robert N. Wilson received a director stock option covering 20,000 common shares on October 1, 2026. The option has an exercise price of $1.64 per share and expires September 30, 2036. Beginning August 19, 2026, 1/12th of the option shares vest in equal monthly installments over one year; the option will be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) may offer and sell common stock with an aggregate offering price of up to $25,000,000 from time to time under its at-the-market offering agreement with H.C. Wainwright & Co., dated August 11, 2023.
CalciMedica, Inc. may offer and sell up to $25,000,000 in aggregate gross sales of common stock from time to time through H.C. Wainwright & Co., LLC as sales agent in an at-the-market offering. Sales may be made at prevailing market prices through Nasdaq, other U.S. trading markets, market makers or negotiated transactions. Wainwright is not required to sell a specific amount and will use commercially reasonable efforts; its commission is 3.0% of gross sales price for each sale.
CalciMedica intends to use net proceeds for general corporate purposes, including research and development, clinical trials, capital expenditures and working capital, and may use some for complementary assets or businesses. An illustrative scenario assuming 14,749,262 shares sold at $1.695 per share for $25,000,000 gross proceeds estimates dilution of $0.285 per share. The auditor’s report on the company’s 2025 financial statements includes an explanatory paragraph relating to going-concern uncertainty.
At CalciMedica, Inc., Chief Medical Officer Sudarshan Hebbar received an employee stock option covering 180,000 shares of common stock on September 24, 2026, with an exercise price of $1.74 per share. The option vests in equal monthly installments of 1/48th over four years, beginning September 24, 2026. His reported direct option position after the award covered 180,000 shares.
CalciMedica, Inc. Chief Scientific Officer Kenneth A. Stauderman received an award of 180,000 employee stock options on September 24, 2026, covering the right to buy common stock at an exercise price of $1.74 per share. Beginning September 24, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. The options expire September 23, 2036; the reported resulting position was 180,000 options held directly.